Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 10, 2022 7:30 AM EDT

First quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression

 First quarter 2022 CAPLYTA new and total prescriptions increased 63% and 45%, respectively, versus the fourth quarter 2021   First quarter 2022 CAPLYTA new and total prescriptions increased 154% and 134%, respectively, versus the same period in 2021   New-to-brand CAPLYTA prescriptions, representing new patient starts, have increased approximately 300% following bipolar depression... More